- Hammond J
- Leister-Tebbe H
- Gardner A
- et al.
However, evidence on paxlovid in high-risk patients who are immunocompromised is in short supply.
- Belsky JA
- Tullius BP
- Lamb MG
- Sayegh R
- Stanek JR
- Auletta JJ
Diagnosis and treatment plan for COVID-19 (trial version 9).
Viral elimination beyond 10 days since diagnosis of SARS-CoV-2 infection established by PCR was defined as a prolonged elimination.
- Agarwal A
- Rochwerg B
- Lamontagne F
- et al.
including those who are hospitalised, and unvaccinated in particular, in order to facilitate viral eradication.
The study protocol was approved by the ethics committees of Renji Hospital (2022-014-A). The study is supported by the Shanghai Hospital Development Center (SHDC; SHDC2020CR1015B) and Shanghai Municipal Health Commission (202040291). De-identified participants’ data will be available on reasonable request to the corresponding author. All the authors declare no competing interests. FS and YL contributed equally to this manuscript.
Supplementary Material
References
- 1.
Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic.
Lancet. 2022; 399: 2011-2012
- 2.
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.
N Engl J Med. 2022; 386: 1397-1408
- 3.
COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients.
J Infect. 2021; 82: 329-338
- 4.
Diagnosis and treatment plan for COVID-19 (trial version 9).
Int J Epidemiol Infect Dis. 2022; 49: 73-80
- 5.
A living WHO guideline on drugs for covid-19.
BMJ. 2020; 370m3379
Article Info
Publication History
Identification
DOI: https://doi.org/10.1016/S1473-3099(22)00430-3
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirect